LiFE: Leading Innovation for the Future Ecosystem in Haemophilia

LiFE: Leading Innovation for the Future Ecosystem in Haemophilia is sponsored by Roche. A global strategic partnership program from Roche supporting initiatives that aim to address important gaps in the care of people living with Haemophilia A.

Roche | LiFE: Leading Innovation for the Future Ecosystem in Haemophilia LiFE: Leading Innovation for the Future Ecosystem in Haemophilia Partnership Science Haematology Haemophilia Innovation Research and development Leadership At Roche, our vision is a haemophilia free life for all. Achieving this requires commitment and partnership with the haemophilia A community.

LiFE is a global strategic partnership program from Roche supporting initiatives that aim to address important gaps in the care of people living with Haemophilia A. LiFE aims to support clinicians, researchers, healthcare organisations, and multidisciplinary teams working to improve outcomes for people living with Haemophilia A.

Improve evidence infrastructure and outcomes measurement by advancing the development, harmonisation of novel patient-centered endpoints and registries Build specialised capability and multidisciplinary workforce expertise to prepare health systems to integrate innovative therapeutic platforms into routine practice.

Translate scientific innovation into daily clinical practice by deploying practical clinical tools, decision-support frameworks, and coordinated care delivery pathways that optimise daily patient management LiFE supports projects in three priority areas. 1.

Data & Evidence Infrastructure We are interested in initiatives that strengthen the generation, collection, harmonisation, or application of meaningful clinical data in haemophilia A, with two focus areas: Development of new endpoints beyond bleeding rates (ABR), with a pathway toward regulatory and payer acceptance Registry initiatives addressing relevant current and future evidence gaps Investigator-initiated studies (i.e. as interventional trials) are out of scope for LiFE.

2. Education & Workforce Capability We welcome projects that support education, capability building, and development of the future workforce in haemophilia care.

Educational initiatives focused on evolving care models Programs addressing aging and comorbidities Musculoskeletal health and physical activity programs Multidisciplinary care education Training initiatives for future treaters and researchers Practical educational tools supporting implementation of innovation into care Non-Clinical Education (general professional development, business administration qualifications , or non-healthcare-specific skills training) is out of scope for LiFE.

3. Guidance & Tools for Optimal Patient Management We encourage initiatives that help translate advances in science into practical improvements in clinical care.

Multidisciplinary care pathways Monitoring and follow-up frameworks Clinical decision-support tools Models supporting personalized care approaches Tools that support coordination across care teams Treatment guidelines are out of scope for LiFE Eligibility and Participation We encourage applications from: Haemophilia treatment centers Healthcare institutions and organisations Academic and research institutions Research networks and collaborative groups Multi-stakeholder collaborations initiatives are encouraged.

Applications must be submitted by legal entities. LiFE has an expected duration of three years. During this time, it will support projects through different funding mechanisms, including grants, sponsorships, consortia and partnerships.

Funding will be distributed across 3 tiers: Tier 1: Up to 75,000 CHF for small, local projects or pilot initiatives Tier 2: Up to 150,000 CHF for medium sized projects or multicenter initiatives Tier 3: Up to 300,000 CHF for multistakeholder or highly scalable initiatives Proposals must demonstrate viability across all five of these core areas to proceed to final funding consideration: Strategic Alignment and Scientific Merit How clearly does the proposal align with one or more of the three LiFE priority areas ( Data & Evidence Infrastructure , Education & Workforce Capability , or Guidance & Practical Tools )?

Is the underlying scientific, clinical, or structural rationale robust and evidence-based? Expected Outcomes and Success Metrics Does the initiative have a clear, realistic plan to measurably improve evidence infrastructure, patient outcomes measurement, workforce capacity, or daily clinical care delivery? Are project milestones achievable, and are success measures defined using objective, quantifiable KPIs?

Unmet Need and Differentiation Does the project address a highly significant, documented structural gap in Haemophilia A care? Does it offer a unique, differentiated approach that avoids duplicating existing public registries, standardised educational platforms, or academic tools? Feasibility, Execution, and Budget Is the project plan realistic, well-structured, and achievable within the proposed timeline and resources?

Is the requested budget transparent, fully itemised, and appropriate for the scale of the proposed activities? Does the project team and host organization possess the necessary clinical, academic, or research experience and administrative capability to execute the project successfully?

While not mandatory, the following criteria are desirable: Does the initiative encourage meaningful collaboration across the haemophilia ecosystem by involving multidisciplinary partners? Can the tools, educational curricula, or data frameworks developed in this project be easily expanded, adapted, or replicated across other global markets to maximise systemic impact?

Does the proposal outline a credible long-term plan for the initiative to be sustained beyond the initial Roche funding period without ongoing financial dependence? LIFE accepts proposals through two submission cycles each year that will be published on this website. Funding is subject to appropriate legal and compliance review and we may not be able to fund certain types of initiatives in all countries.

To ensure alignment with local laws, regulations, and compliance requirements, applicants are encouraged to liaise with their local Roche point of contact before submission. The current submission cycle is open until end of July 2026 Please submit proposals to: global. lifeprogram@roche.

com Applicants will be asked to submit the following materials: A signed letter from the applying organisation addressed to: The letter should include: Name of the applying organisation Address, city, zip/postal code, and country Name and email address of the main contact person Amount requested from Roche Total project budget and budget breakdown Proposed benefits for Roche - if any- and/or any in-kind / non-monetary support from Roche needed -if any.

Start and end dates of the proposed activity, where applicable Venue details, where applicable Signature and date from an authorised representative of the organisation Applicants should provide the project outline including: Focus Area : Data and Evidence, Education and Workforce Capability, Guidance and Practical Tools for Optimal Patient Management Scientific and Clinical Rationale : Referenced rationale detailing the scientific, clinical, or structural basis of the project.

Problem Statement, Unmet Need, and Differentiation : A description of the specific, unaddressed gap in Haemophilia A care that this initiative aims to resolve and unique differentiating value it offers. Project Methodology and Implementation Plan : Description of the technical approach, the project timelines and roles, responsibilities, and decision-making structures.

Financial Overview and Justification: Selected Funding Tier, total amount requested, and budget breakdown. Expected Outcomes, Success Metrics, and Performance Indicators. Project Personnel Qualifications and Experience.

Additional Indicators, where applicable : Multi-Stakeholder Value. Scalability and/or replicability strategy. Long term sustainability Plan.

Where applicable, applicants may also include: Additional supporting documentation Description of anticipated target audience and stakeholder reach Description of any planned visibility or collaboration elements related to Roche support, if applicable Governance & Legal Framework LiFE is overseen through an internal governance process involving cross-functional review from medical, scientific, operational, legal, and compliance representatives.

All proposals undergo review before funding decisions are made. Roche reserves the right to decline any request that does not meet the applicable criteria. An applicable contract will be signed between Roche and the organization for all funding related to LiFE.

What types of projects are eligible for LiFE funding? LiFE supports initiatives that address structural or practical gaps in haemophilia A across three categories: Data and Evidence, with a focus on registries and new endpoints with a path to regulatory and payer acceptance.

Education and Workforce Capability Guidance and Tools for Optimal Patient Management Both new initiatives and existing projects seeking support for expansion or broader implementation may be considered. What projects are out of scope? The following are generally out of scope: Independent Clinical Research: Investigator-Sponsored Studies these must be routed through standard, independent Roche IIS channels.

Non-Clinical Education: General professional development, business administration qualifications (e.g., MBAs), or non-healthcare-specific skills training. Formal Clinical Guidelines: The creation of formal treatment guidelines, which must remain under the exclusive purview of independent Medical/Scientific Societies.

Individual Requests: Funding requests for individuals, including personal travel grants, congress attendance sponsorships, or individual fellowships outside official institutional programs. Applications are open to legal entities, including haemophilia treatment centers, healthcare institutions and organisations, academic and research institutions, research networks and collaborative groups.

Are multistakeholder collaborations encouraged? Yes. LiFE encourages scalable initiatives and collaborations that can generate broader learning or impact across healthcare systems.

How are proposals evaluated? Applications are reviewed based on: Strategic Alignment and Scientific Merit Expected Outcomes and Success Metrics Unmet Need and Differentiation Feasibility, Execution, and Budget Additional criteria (not mandatory): Multi-Stakeholder Value, Scalability, Sustainability Does Roche participate in the execution of projects?

Roche’s involvement depends entirely on the contracting framework of the approved initiative: Grants and Sponsorships: The project is executed entirely independently by the applicant. To ensure scientific integrity and autonomy, Roche does not participate in the hands-on execution or development of the project.

Partnerships and Consortia: Roche may actively collaborate or co-create with partners on specific project deliverables, where aligned with the program's strategic objectives. For all funded initiatives, Roche provides operational oversight to ensure funding governance, tracking of agreed milestones, and compliance reporting. When are submission windows open?

LiFE plans to operate with two proposal cycles annually, which will be posted on this website. Continue sharing inspiring stories Discover how Roche is transforming haemophilia A care through innovation, partnerships and improved access to treatment. Learn about our commitment to helping people with haemophilia live their best lives.

Learn about haemophilia A in infants, its impact on families, key symptoms to watch for, and why early diagnosis and prophylactic treatment are crucial for better outcomes. Haemophilia treatment for all: A partnership for better access The WFH Humanitarian Aid Program, supported by Roche, is improving access to haemophilia treatment in developing countries.

Learn how the partnership is helping people access diagnosis and prophylactic care Raising the bar in haemophilia A care Discover how Dr. John Pasi from Roche envisions the future of haemophilia A care, driven by innovation, personalisation, and a commitment to meeting the evolving needs of people worldwide. Rare within rare: Women with haemophilia Haemophilia is rare in men – but it’s even more rare in women.

Learn more about this gap in haemophilia care, and how it can be addressed. Busting myths in haemophilia There are many misconceptions about haemophilia - our interactive flashcards dispel some of the most common of these. Progress in haemophilia: A personal perspective The haemophilia community is united and strong.

Find out more about the haemophilia community and progress being made in the field from Brian O’Mahony, Chief Executive of the Irish Haemophilia Society.